April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Toll-like Receptor 4, Low Molecular Weight Hyaluronic Acid and Cytokine Response in Trabecular Meshwork Cells
Author Affiliations & Notes
  • Jeffrey P. Mayer
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • Algis Kasniunas
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • Ryan D. McCarty
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • Stephen N. Schwartz
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • Beatrice Y.J.T. Yue
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
  • Paul A. Knepper
    Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, Illinois
    Department of Ophthalmology, Northwestern University, Chicago, Illinois
  • Footnotes
    Commercial Relationships  Jeffrey P. Mayer, None; Algis Kasniunas, None; Ryan D. McCarty, None; Stephen N. Schwartz, None; Beatrice Y.J.T. Yue, None; Paul A. Knepper, Alcon Research Ltd. (R)
  • Footnotes
    Support  Alcon Research Ltd. -- On the prevention and treatment of primary open-angle glaucoma
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 4652. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jeffrey P. Mayer, Algis Kasniunas, Ryan D. McCarty, Stephen N. Schwartz, Beatrice Y.J.T. Yue, Paul A. Knepper; Toll-like Receptor 4, Low Molecular Weight Hyaluronic Acid and Cytokine Response in Trabecular Meshwork Cells. Invest. Ophthalmol. Vis. Sci. 2011;52(14):4652.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

Innate immunity is the first line of defense and is rapidly activated by cell trauma and infection leading to NF-Κβ activation responsive genes. Recent evidence suggests that low molecular weight hyaluronic acid (HA) signals through CD44-TLR-4-MD-2 receptor complex. The purpose of this study is to determine if low molecular weight HA elicits a cytokine response through Toll-like receptor 4 in trabecular meshwork (TM) cells.

 
Methods:
 

TM primary cells were plated at 40,000 cells/well in 0.5 mL 10% FBS complete media for cell viability studies. Cells were treated for 24 hours with 40 µg/ml of low and high molecular weight HA, PBS control, and 25 µg LPS. Cells were harvested and counted using trypan blue. For cytokine studies, cells were treated with low and high molecular weight HA, and PBS control, and cell lysates were obtained after 6, 24, and 48 hours. The concentrations of the cytokines TNF-α, IFNr, GCSF, GMCSF, IL-1α, IL-8, IP-10 and Rantes were measured using a Human Inflammation ELISA strip (Signosis).

 
Results:
 

The data was corrected relative to the PBS control. The results indicated cell viabilities of 61.7% (+5.16%) for LPS, 80.2% (+3.61%) for 40 µg low molecular weight HA (P<0.02 compared to control), and 87.7% (+3.51%) for high molecular weight HA. Cytokine analysis profile of high molecular weight HA treated cells indicated decreased Rantes, GMCSF, IFNr, TNF-α and GCSF cytokine concentrations by 48 hours. Low molecular weight HA increased concentration of GCSF and IP-10 by 48 hours, and decreased the concentration of Rantes, GMCSF, a potent CNS neuroprotective cytokine, and TNF-α. Neither treatment of HA had an effect on IL-8 concentrations.  

 
Conclusions:
 

Our results indicate that administration of low molecular weight HA to TM cells decreases cell viability and induces cytokine responses in a time-dependent manner which may have pro-inflammatory as well as neuroprotective effects on TM cells.

 
Keywords: cytokines/chemokines • immunomodulation/immunoregulation • trabecular meshwork 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×